Title:
NOVEL USE OF 3-(4-(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2022/211303
Kind Code:
A1
Abstract:
A 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes the expression of the myogenic factors MyoG and MyHC while inhibiting the expression of the muscle atrophy factor atrogin-1, promotes the formation of myotubes, and inhibits myocyte apoptosis, and thus can promote myogenesis and inhibit muscle atrophy.
Inventors:
YOO HYE JIN (KR)
HWANG HWAN JIN (KR)
HWANG HWAN JIN (KR)
Application Number:
PCT/KR2022/003384
Publication Date:
October 06, 2022
Filing Date:
March 10, 2022
Export Citation:
Assignee:
HYUNDAI PHARM CO LTD (KR)
International Classes:
A61K31/357; A61P21/00; C07D317/72
Domestic Patent References:
| WO2019108046A1 | 2019-06-06 | |||
| WO2014171762A1 | 2014-10-23 |
Foreign References:
| US20200039957A1 | 2020-02-06 | |||
| US20130045990A1 | 2013-02-21 | |||
| KR101666659B1 | 2016-10-14 |
Other References:
HAMDOUCHI CHAFIQ, KAHL STEVEN D., PATEL LEWIS ANJANA, CARDONA GUEMALLI R., ZINK RICHARD W., CHEN KEYUE, EESSALU THOMAS E., FICORIL: "The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470)", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 59, no. 24, 22 December 2016 (2016-12-22), US , pages 10891 - 10916, XP055972684, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.6b00892
Attorney, Agent or Firm:
DANA PATENT LAW FIRM (KR)
Download PDF: